Immunex: One of the first biotechnology companies to go public, Immunex was still largely engaged in R&D with no therapeutic products on the market yet. Rather than try to explain the complex kinds of cutting-edge scientific research Immunex engaged in, for its premier annual report, we focused on the diseases (autoimmune disorders, cancer, infectious diseases) that they were targeting and discussed the millions of people who would benefit if they succeed. This approach helped shareholders and financial analysts better understand the company’s mission.

Immunex: Cover for annual report on six distinct processes on bringing a product to market.